Expert: Companies should embrace ‘sustainable compliance’ to avoid 483s, warning letters
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesCDERComplianceGMPHealth Authority meeting and communication strategyPharmaceuticalsRegulatory Intelligence/PolicyUnited States